Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro
- 241 Downloads
E-cadherin is a transmembrane glycoprotein which mediates epithelial cell-to-cell adhesion function as a tumor suppressor and frequently loss of expression in a wide spectrum of human cancer. However, recent studies demonstrated that E-cadherin was always over-expressed in inflammatory breast cancer (IBC) specimen and cell lines, which is a clinical extreme malignancy of breast cancer. It is hypothesized that the gain and not the loss of the E-cadherin axis contributes to the IBC unique phenotype. To test this assumption, we generated dominant negative mutant E-cadherin high-expression inflammatory breast cancer cells by introduced dominant negative mutant E-cadherin (H-2kd-E-cad) cDNA into human IBC SUM149 cells. Our studies demonstrated that the ability of invasion of SUM149 cells was significantly inhibited by H-2kd-E-cad via down-regulation of MMP-1 and MMP-9 expression. The underlying signal pathway of MAPK phosphorylated Erk 1/2(P44/42) in H-2kd-E-cad-transfected SUM149 cells was significantly down-regulated compared to parental and mock contrast. Our studies provided further functional evidence as the gain of E-cadherin expression dedicated to the IBC malignant phenotype and the blockage of MAPK/Erk activation maybe a promising therapeutic target.
KeywordsE-cadherin Inflammatory breast cancer MMP MAPK
We thank Dr. Ioannis S. Vizirianakis and Professor Stephen P. Ethier for the plasmid pcDNA3.1(-)Myc/His and the SUM149 cell line This research was supported in part by grants from the Outstanding Young Investigator Award of National Natural Science Foundation of China (No. 30025015), National Natural Science Foundation of China (30371580) and National Key Project of China (No. 2001BA703BO5), and the Grant from Shanghai Science and Technology Committee (03J14019).
- van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H et al (1999) A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 5:2511–219PubMedGoogle Scholar